29.3  0.39 (1.35%)		12-26 16:00
Open: 28.66 High: 29.465 Volume: 472,618		Pre. Close: 28.91 Low: 28.43 Market Cap: 1,990(M)

Short term
Mid term
Targets	6-month :	35.5	1-year :	41.47
Resists	First :	30.39	Second :	35.5
Pivot price	28.72
Supports	First :	24.55	Second :	20.94
MAs	MA(5) :	29.11	MA(20) :	28.32
	MA(100) :	27.15	MA(250) :	0
MACD	MACD :	0.8	Signal :	0.8
%K %D	K(14,3) :	61.3	D(3) :	65.3
RSI	RSI(14): 58
52-week	High :	49.45	Low :	19.5

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ QDEL ] has closed below upper band by 30.6%. Bollinger Bands are 53.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	29.5 - 29.61	29.61 - 29.7
Low:	28.14 - 28.27	28.27 - 28.38
Close:	29.09 - 29.31	29.31 - 29.48

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Wed, 24 Dec 2025
QuidelOrtho (NASDAQ:QDEL) Share Price Passes Above 200-Day Moving Average - Here's Why - MarketBeat

Wed, 17 Dec 2025
Innovating Diagnostics and What's Next - Sahm

Tue, 16 Dec 2025
QuidelOrtho Corporation (NASDAQ:QDEL) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat

Sat, 13 Dec 2025
Beaconlight Capital LLC Sells 209,652 Shares of QuidelOrtho Corporation $QDEL - MarketBeat

Thu, 11 Dec 2025
QuidelOrtho (NASDAQ:QDEL) Q3 Earnings: Leading The Medical Devices & Supplies - Imaging, Diagnostics Pack - Finviz

Wed, 03 Dec 2025
Why QuidelOrtho (QDEL) Stock Is Up Today - Finviz

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	68 (M)
Shares Float	63 (M)
Held by Insiders	0.9 (%)
Held by Institutions	122.9 (%)
Shares Short	11,480 (K)
Shares Short P.Month	9,020 (K)

EPS	-17.41
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	29.98
Profit Margin	-43.5 %
Operating Margin	6.6 %
Return on Assets (ttm)	1.4 %
Return on Equity (ttm)	-45.2 %
Qtrly Rev. Growth	-3.8 %
Gross Profit (p.s.)	18.84
Sales Per Share	39.89
EBITDA (p.s.)	8.5
Qtrly Earnings Growth	0 %
Operating Cash Flow	37 (M)
Levered Free Cash Flow	221 (M)

PE Ratio	-1.69
PEG Ratio	0
Price to Book value	0.97
Price to Sales	0.73
Price to Cash Flow	53.79

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.